Why the study?
It remains unclear whether assessing myocardial viability before coronary revascularization meaningfully impacts outcomes in patients with ischemic cardiomyopathy.
Does assessing myocardial viability before coronary revascularization improve cardiac function and survival in patients with ischemic cardiomyopathy?
Meta-Analysis
Does assessing myocardial viability before coronary revascularization improve cardiac function and survival in patients with ischemic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Myocardial viability assessment before revascularization in ischemic cardiomyopathy is associated with improved left ventricular recovery and survival in patients with viable myocardium.
This review explores whether assessing myocardial viability before coronary revascularization meaningfully impacts outcomes in patients with ischemic cardiomyopathy. By synthesizing evidence from studies employing imaging techniques such as CMR, PET, SPECT, and dobutamine stress echocardiography, we examined associations between viability status and improvements in cardiac function and survival. Our findings suggest that patients with viable myocardium tend to derive greater benefit from revascularization, particularly in terms of left ventricular recovery and reduced mortality. These results highlight the potential value of viability imaging in guiding treatment decisions and support its selective use in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kusi-Yeboah et al. (2025) conducted a meta-analysis in Ischemic cardiomyopathy with severely reduced LVEF. Myocardial viability vs. Non-viable myocardium was evaluated on Improvement in LVEF following revascularization (MD 4.03%, 95% CI 3.76-4.31, p=<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: